Vaxcyte CAO Sells $180,000 in Company Stock

Elvia Cowan, the Chief Accounting Officer of Vaxcyte, sold 3,000 shares of the company's stock.

Apr. 9, 2026 at 11:54am

Got story updates? Submit your updates here. ›

An extreme close-up of heavy, industrial-looking mechanical components and gears in shades of steel gray, bronze, and black, conceptually representing the intricate financial infrastructure and operations of a biotech company.An extreme close-up of Vaxcyte's financial machinery and operations reveals the complex inner workings behind the biotech company's vaccine development.San Carlos Today

Elvia Cowan, the Chief Accounting Officer of Vaxcyte, Inc. (NASDAQ:PCVX), sold 3,000 shares of the company's stock on Tuesday, April 7th. The shares were sold at an average price of $60.00, resulting in a total transaction of $180,000. Following the sale, Cowan directly owned 28,975 shares of the company's stock, valued at approximately $1,738,500.

Why it matters

This transaction represents a 9.38% decrease in Cowan's ownership stake in Vaxcyte. Insider transactions like this can provide insight into management's views on the company's prospects and valuation.

The details

The sale was executed under a pre-arranged Rule 10b5-1 trading plan, which allows corporate insiders to sell shares at predetermined times to avoid allegations of insider trading. Vaxcyte is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases.

  • The shares were sold on Tuesday, April 7th, 2026.

The players

Elvia Cowan

The Chief Accounting Officer of Vaxcyte, Inc.

Vaxcyte, Inc.

A clinical-stage biotechnology company focused on developing a new generation of preventive vaccines.

Got photos? Submit your photos here. ›

The takeaway

This insider sale by Vaxcyte's Chief Accounting Officer, while not necessarily indicative of any broader concerns, does provide some insight into management's views on the company's current valuation and prospects. Investors will likely continue to monitor Vaxcyte's progress as it advances its pipeline of novel vaccine candidates.